A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Acute Myeloid Leukemia
Related studies linked through entity extraction aliases.
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
- Status
- RECRUITING
- Phase
- NA
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Status
- RECRUITING
- Phase
- PHASE2
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- Status
- RECRUITING
- Phase
- PHASE2
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
- Status
- SUSPENDED
- Phase
- PHASE1
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.
- Status
- UNKNOWN
- Phase
- N/A
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
- Status
- RECRUITING
- Phase
- PHASE3
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
- Status
- TERMINATED
- Phase
- PHASE2
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2